This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

4 Biotech Penny Stocks to Buy: Navellier

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK (InvestorPlace) -- Some of the hottest penny stocks to buy now are in the biotech sector. Start-ups and early-phase biotechnology companies can provide explosive profit potential for investors who are in on the ground floor of a game-changing medical technology or blockbuster drug.

That said, finding hot penny stocks in the biotech sector is no easy task. There are lots of micro-caps and pink sheet stocks out there that wreak havoc on the portfolios of penny stock investors. But buying penny stocks doesn't have to be an all-out gamble -- by screening for investments with a decent market cap ($100 million or more) and a listing on a major exchange, you can find ultracheap stocks that are very fast movers but considerably less risky.

Here are my favorite four biotech penny stocks to buy now:

YM BioSciences (YMI): The first stock on the list is biopharmaceutical company YM BioSciences, which develops products for the treatment of cancer. In the last 12 months, YMI stock has gained 63%. More recently, YMI is up 8% year to date and is trading near its 52-week high of $2.52.

Zalicus (ZLCS): Since the start of 2011, has watched its stock value rise 44%, compared with much smaller gains by the broader markets. This biopharmaceutical company, which focuses on the treatment of pain and inflammation, has experienced stock growth of 70% since last April. Buy this stock with a 52-week range of $1.01 to $2.72. Zalicus is one of InvestorPlace.com's 10 Best Stocks for 2011.

AEterna Zentaris (AEZS): Drug development company AEterna Zentaris specializes in oncology and endocrine therapy. Since the start of 2011, this penny stock has raised its stock value 8%. Investors are even more thrilled to see 52-week growth of 87%.

  • Related Article:Why Gold Will Hit $5,000 Soon
  • Dynavax Technologies (DVAX): Known for discovering and developing products for the prevention and treatment of infectious diseases, asthma and autoimmune diseases, Dynavax Technologies has gained 36% in the last six months. Going further back, this penny stock has shown impressive gains of 84% in the last year.

    As of this writing, Louis Navellier did not own a position in any of the stocks named here.

    One of Wall Street's renowned growth investors, Louis Navellier is the editor of four investing newsletters: Emerging Growth (formerly known as MPT Review), Blue Chip Growth, Quantum Growth and Global Growth. His longest-running publication, Emerging Growth, has a track record of beating the market nearly 3 to 1. Navellier is the author of a BusinessWeek bestseller, "The Little Book That Makes You Rich," and the chairman and founder of Navellier & Associates, Inc.

    Select the service that is right for you!

    COMPARE ALL SERVICES
    Action Alerts PLUS
    Try it NOW

    Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    • Weekly roundups
    TheStreet Quant Ratings
    Try it NOW
    Only $49.95/yr

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    • Upgrade/downgrade alerts
    Stocks Under $10
    Try it NOW

    David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    • Weekly roundups
    Dividend Stock Advisor
    Try it NOW

    Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Alerts when market news affect the portfolio
    • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
    Real Money Pro
    Try it NOW

    All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

    Product Features:
    • Real Money + Doug Kass Plus 15 more Wall Street Pros
    • Intraday commentary & news
    • Ultra-actionable trading ideas
    Options Profits
    Try it NOW

    Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

    Product Features:
    • 100+ monthly options trading ideas
    • Actionable options commentary & news
    • Real-time trading community
    • Options TV
    To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
    Submit an article to us!
    DOW 17,106.70 +29.83 0.17%
    S&P 500 2,000.02 +2.10 0.11%
    NASDAQ 4,570.6370 +13.29 0.29%

    Brokerage Partners

    Rates from Bankrate.com

    • Mortgage
    • Credit Cards
    • Auto

    Free Newsletters from TheStreet

    My Subscriptions:

    After the Bell

    Before the Bell

    Booyah! Newsletter

    Midday Bell

    TheStreet Top 10 Stories

    Winners & Losers

    Register for Newsletters
    Top Rated Stocks Top Rated Funds Top Rated ETFs